AR066667A1 - PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT - Google Patents
PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENTInfo
- Publication number
- AR066667A1 AR066667A1 ARP080102158A ARP080102158A AR066667A1 AR 066667 A1 AR066667 A1 AR 066667A1 AR P080102158 A ARP080102158 A AR P080102158A AR P080102158 A ARP080102158 A AR P080102158A AR 066667 A1 AR066667 A1 AR 066667A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- pharmaceutical compositions
- lipstatine
- combination
- hmg coa
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 title 1
- 239000001257 hydrogen Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 2
- 229960001243 orlistat Drugs 0.000 abstract 2
- 229960000672 rosuvastatin Drugs 0.000 abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 2
- 229960002855 simvastatin Drugs 0.000 abstract 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Composiciones farmacéuticas caracterizadas por estar compuestas por la combinacion sinérgica de un agente derivado hidrogenado de lipstatina, tal como lo es el principio activo: Orlistat y un agente inhibidor de la enzima HMG-CoAreductasa, tal como lo son los principios activos: Simvastatina y/o Rosuvastatina, además de excipientes farmacéuticamente aceptables; en donde los rangos de concentracion que se encuentran presentes en la formulacion para el Orlistat son de 60.0mg. a 120.0 mg., para la Simvastatina son de 20.0 mg. a 40.0 mg. y para la Rosuvastatina son de 5.0 a 10.0 mg; mismos que se encuentran formulados en una sola unidad de dosificacion para ser administradas por vía oral, las cuales están indicadaspara la prevencion y/o tratamiento de la hipercolesterolemia, trigliceridemia, el sobrepeso y la obesidad.Claim 1: Pharmaceutical compositions characterized by being composed of the synergistic combination of a hydrogenated derivative agent of lipstatin, such as the active ingredient: Orlistat and an inhibitor of the enzyme HMG-CoAreductase, such as the active ingredients: Simvastatin and / or Rosuvastatin, in addition to pharmaceutically acceptable excipients; where the concentration ranges that are present in the formulation for Orlistat are 60.0mg. at 120.0 mg., for Simvastatin they are 20.0 mg. at 40.0 mg and for Rosuvastatin they are 5.0 to 10.0 mg; same that are formulated in a single dosage unit to be administered orally, which are indicated for the prevention and / or treatment of hypercholesterolemia, triglyceridemia, overweight and obesity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007006092A MX2007006092A (en) | 2007-05-21 | 2007-05-21 | Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent. |
| PCT/MX2008/000062 WO2008143491A1 (en) | 2007-05-21 | 2008-05-19 | Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066667A1 true AR066667A1 (en) | 2009-09-02 |
Family
ID=40032121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102158A AR066667A1 (en) | 2007-05-21 | 2008-05-21 | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR066667A1 (en) |
| MX (1) | MX2007006092A (en) |
| UY (1) | UY31096A1 (en) |
| WO (1) | WO2008143491A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110357812A (en) * | 2019-08-03 | 2019-10-22 | 黄泳华 | The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
| CN110314232A (en) * | 2019-08-03 | 2019-10-11 | 黄泳华 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512879A1 (en) * | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
-
2007
- 2007-05-21 MX MX2007006092A patent/MX2007006092A/en not_active Application Discontinuation
-
2008
- 2008-05-19 UY UY31096A patent/UY31096A1/en not_active Application Discontinuation
- 2008-05-19 WO PCT/MX2008/000062 patent/WO2008143491A1/en not_active Ceased
- 2008-05-21 AR ARP080102158A patent/AR066667A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31096A1 (en) | 2008-11-28 |
| WO2008143491A1 (en) | 2008-11-27 |
| MX2007006092A (en) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080284L (en) | Cannabionoid active pharmaceutical ingredient for improved dosage forms | |
| BRPI0508540A (en) | compound, pharmaceutical composition, and use of a compound | |
| CO6251259A2 (en) | PHARMACEUTICAL FORMULATIONS OF ESTRIOL IN LOW DOSE | |
| AR075735A1 (en) | PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE | |
| ECSP066990A (en) | FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO | |
| ATE493973T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN | |
| WO2009026473A3 (en) | Stabilized therapeutic compositions and formulations | |
| WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
| BR112012009857A2 (en) | solid pharmaceutical compositions containing an integrase inhibitor | |
| CL2010000524A1 (en) | Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts. | |
| AR068820A1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE | |
| CL2009001267A1 (en) | Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis. | |
| CL2024003616A1 (en) | Oral pharmaceutical composition and use for the therapy of progressive fibrosing interstitial lung diseases. | |
| AR066666A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT | |
| BRPI0409878A (en) | compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds | |
| AR066667A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATINE AGENT AND AN HMG COA REDUCTASA INHIBITING AGENT | |
| RU2013105513A (en) | Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases | |
| CO6270220A2 (en) | PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES | |
| RU2011113733A (en) | Derivatives of 1-amino-alkylcyclohexane for the treatment of cognitive impairment in noise in the ears | |
| RU2012136190A (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT | |
| AR067320A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS | |
| ATE460934T1 (en) | PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN | |
| AR037543A1 (en) | METHOD FOR CANCER THERAPY AND PHARMACEUTICAL COMPOSITION | |
| AR067038A1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-COA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTROINTESTINAL ENZYME LIPASE | |
| AR067700A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINE ENZYME INDICATED FOR THE CONTOL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |